NCT06930638 MitoQ and Ischemic Conditioning To Assess Vascular Health Outcomes
| NCT ID | NCT06930638 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Medical College of Wisconsin |
| Condition | Stroke |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2025-07-22 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 30 participants in total. It began in 2025-07-22 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Stroke survivors have compromised vascular function which may contribute to secondary stroke risk, cardiovascular disease, and may limit their exercise tolerance. Preliminary data shows a single bout of ischemic conditioning or oral ingestion of an over-the-counter antioxidant supplement called MitoQ may improve vascular function and muscle activity in individuals post-stroke.
Eligibility Criteria
Inclusion Criteria: * 18 - 85 years of age * Cortical or sub-cortical stroke ≥ 6 months ago with residual hemiparesis * Able to give informed consent and follow 2-step command. * English Speaking Exclusion Criteria: * Unable to stand from chair without physical assistance from another person (able to use assistive device). * History of blood clots in the extremities or any condition in which compression of the thigh or transient ischemia is contraindicated (i.e., wounds in the leg). * Chronic lasting symptoms (\> 6 months) of severe COVID-19 (i.e., hospitalization) * History of head trauma or concussion within the past 6 months * Comorbid neurological disorder * Peripheral vascular disease * Myocardial infarction or arrhythmia in the previous year * Resting SBP ≥180 mmHg or DBP ≥ 100 mmHg * Pregnant or breastfeeding. * Other significant medical condition likely to influence study or jeopardize safety as assessed by the Primary Investigator
Contact & Investigator
Matthew Durand, PhD
PRINCIPAL INVESTIGATOR
Medical College of Wisconsin
Frequently Asked Questions
Who can join the NCT06930638 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 85 Years, studying Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06930638 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06930638 currently recruiting?
Yes, NCT06930638 is actively recruiting participants. Contact the research team at jnguyen@mcw.edu for enrollment information.
Where is the NCT06930638 trial being conducted?
This trial is being conducted at Milwaukee, United States.
Who is sponsoring the NCT06930638 clinical trial?
NCT06930638 is sponsored by Medical College of Wisconsin. The principal investigator is Matthew Durand, PhD at Medical College of Wisconsin. The trial plans to enroll 30 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.